Начало › Рак на белия дроб с недребноклетъчен тип › Северна Каролина › Durham
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Durham, NC
39 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Durham (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Набиране на участнициФаза 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набиране на участнициФаза 1
- Exelixis Clinical Site #12, Durham
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Набиране на участнициФаза 3
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill · на 10 мили
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Набиране на участнициФаза 3
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Набиране на участнициФаза 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · на 10 мили
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Набиране на участнициФаза 1/2
- Duke Cancer Center Durham, Durham
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Durham
- Clinical Study Site, Chapel Hill · на 10 мили
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Набиране на участнициФаза 3
- Durham VA Health Care System, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Набиране на участнициФаза 1/2
- Duke University School of Medicine, Durham
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Набиране на участнициФаза 2/3
- Duke University Medical Center, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
Набиране на участнициФаза 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · на 10 мили
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Набиране на участнициНаблюдателно проучване
- UNC- Chapel Hill, Chapel Hill · на 10 мили
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- Duke Cancer Institute, Durham
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · на 10 мили
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Набиране на участнициФаза 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · на 10 мили
- University of North Carolina, Chapel Hill · на 10 мили
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Набиране на участнициФаза 1/2
- Duke Cancer Institute, Durham
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- UNC Health - University of North Carolina, Chapel Hill · на 10 мили
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Duke University Medical Center, Durham
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- Duke Cancer Institute, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 2
- University of North Carolina, Chapel Hill · на 10 мили
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Набиране на участнициФаза 1
- Duke Cancer Institute /ID# 276267, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Набиране на участнициФаза 1
- Research Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Набиране на участнициФаза 1
- Duke Cancer Center /ID# 251975, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Durham VA Medical Center, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Набиране на участници
- Durham VA Medical Center, Durham, NC, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Набиране на участнициРанна фаза 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
GEMINI-NSCLC: NSCLC Biomarker Study
Набиране на участнициНаблюдателно проучване
- Duke University, Durham
- UNC, Chapel Hill · на 10 мили
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Chapel Hill · на 10 мили
A Study of NX-1607 in Adults With Advanced Malignancies
Набиране на участнициФаза 1
- University of North Carolina, Chapel Hill · на 10 мили
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Durham
- Рак на гърдата64 проучвания
- Рак (всички видове)58 проучвания
- Множествен миелом37 проучвания
- Остра миелоидна левкемия33 проучвания
- Метастатичен рак33 проучвания
- Рак на простатата32 проучвания
- Рак на белия дроб32 проучвания
- Колоректален рак28 проучвания
- Рак на яйчниците27 проучвания
- Хронична лимфоцитна левкемия27 проучвания
- Сърдечна недостатъчност26 проучвания
- Рак на панкреаса24 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.